MYGN Myriad Genetics Inc

Price (delayed)

$21.32

Market cap

$1.92B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.18

Enterprise value

$1.94B

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The quick ratio has soared by 71% since the previous quarter and by 3.8% year-on-year
Myriad Genetics's revenue has increased by 11% YoY and by 2.6% QoQ
The company's net income has shrunk by 135% YoY but it rose by 4% QoQ
The EPS has plunged by 129% YoY but it has grown by 5% from the previous quarter
The gross margin has declined by 2.3% year-on-year

Key stats

What are the main financial stats of MYGN
Market
Shares outstanding
89.87M
Market cap
$1.92B
Enterprise value
$1.94B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.24
Price to sales (P/S)
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.57
Earnings
Revenue
$753.2M
EBIT
-$259.3M
EBITDA
-$186.1M
Free cash flow
-$184.2M
Per share
EPS
-$3.18
Free cash flow per share
-$2.22
Book value per share
$9.53
Revenue per share
$9.1
TBVPS
$6.15
Balance sheet
Total assets
$1.15B
Total liabilities
$363.3M
Debt
$152.1M
Equity
$783.2M
Working capital
$157.7M
Liquidity
Debt to equity
0.19
Current ratio
2.01
Quick ratio
1.64
Net debt/EBITDA
-0.11
Margins
EBITDA margin
-24.7%
Gross margin
68.6%
Net margin
-35%
Operating margin
-34.2%
Efficiency
Return on assets
-22.6%
Return on equity
-34.7%
Return on invested capital
-61.2%
Return on capital employed
-26.2%
Return on sales
-34.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
-0.37%
1 week
-4.39%
1 month
-1.34%
1 year
-6.53%
YTD
11.39%
QTD
11.39%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$753.2M
Gross profit
$517M
Operating income
-$257.4M
Net income
-$263.3M
Gross margin
68.6%
Net margin
-35%
The company's net income has shrunk by 135% YoY but it rose by 4% QoQ
The net margin has plunged by 112% YoY but it has grown by 6% from the previous quarter
The operating income has shrunk by 83% YoY but it rose by 7% QoQ
The company's operating margin has shrunk by 65% YoY but it rose by 10% QoQ

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
2.24
P/S
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.57
The EPS has plunged by 129% YoY but it has grown by 5% from the previous quarter
MYGN's price to book (P/B) is 18% higher than its 5-year quarterly average of 1.9
The company's equity rose by 15% QoQ but it fell by 12% YoY
Myriad Genetics's revenue has increased by 11% YoY and by 2.6% QoQ
The P/S is 6% lower than the 5-year quarterly average of 2.5

Efficiency

How efficient is Myriad Genetics business performance
MYGN's return on equity has dropped by 187% year-on-year
Myriad Genetics's return on assets has shrunk by 146% YoY but it has increased by 3% QoQ
The return on invested capital has dropped by 104% year-on-year
The ROS has plunged by 69% YoY but it has grown by 9% from the previous quarter

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
The quick ratio has soared by 71% since the previous quarter and by 3.8% year-on-year
Myriad Genetics's current ratio has soared by 58% from the previous quarter
The debt is 81% less than the equity
The debt to equity is down by 34% since the previous quarter but it is up by 19% year-on-year
The debt has contracted by 24% from the previous quarter but it has grown by 4.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.